Belenos and Keymed will now look to initiate Phase III studies for their co-developed drug in Dupixent-dominated CRSwNP.

The post Belenos’ Keymed licensing deal delivers on Phase II win in rhinosinusitis appeared first on Clinical Trials Arena.